Lv5
1240 积分 2022-04-30 加入
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
19天前
已完结
Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma
26天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
1个月前
已完结
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
1个月前
已完结
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
1个月前
已完结
Cancer vaccines and the future of immunotherapy
1个月前
已完结
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
1个月前
已完结
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
1个月前
已完结
Targeting KRAS in cancer
1个月前
已完结
皖公网安备34019202002308
